Next Article in Journal
Atomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management
Next Article in Special Issue
Molecular Mechanisms of the Teratogenic Effects of Thalidomide
Previous Article in Journal / Special Issue
Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 13
Issue 4
10.3390/ph13040075
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Novel Pharmaceutical Target for Cystic Fibrosis

by
Ryosuke Fukuda
and
Tsukasa Okiyoneda
*
Department of Biomedical Chemistry, School of Science and Technology, Kwansei Gakuin University, 2-1 Gakuen, Sanda, Hyogo 669-1337, Japan
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(4), 75; https://doi.org/10.3390/ph13040075
Submission received: 3 March 2020 / Revised: 20 April 2020 / Accepted: 20 April 2020 / Published: 22 April 2020
(This article belongs to the Special Issue Targeted Protein Degradation: From Chemical Biology to Drug Discovery)
Browse Figures
Versions Notes

Abstract

:
Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene decrease the structural stability and function of the CFTR protein, resulting in cystic fibrosis. Recently, the effect of CFTR-targeting combination therapy has dramatically increased, and it is expected that add-on drugs that modulate the CFTR surrounding environment will further enhance their effectiveness. Various interacting proteins have been implicated in the structural stability of CFTR and, among them, molecules involved in CFTR ubiquitylation are promising therapeutic targets as regulators of CFTR degradation. This review focuses on the ubiquitylation mechanism that contributes to the stability of mutant CFTR at the endoplasmic reticulum (ER) and post-ER compartments and discusses the possibility as a pharmacological target for cystic fibrosis (CF).

1. Introduction

Cystic Fibrosis (CF) is a lethal recessive disease caused by loss-of-function mutations in the CFTR (cystic fibrosis transmembrane conductance regulator). CF frequently occurs among Caucasians (about 1 in 3500), and the number of patients is more than 90,000 world-wide (US: approximately 30,000, Europe: approximately 48,000) [1]. CF patients present with progressive disease throughout the body, including in the respiratory tract, digestive tract, and exocrine organs (pancreas, testis, sweat glands, etc.). Shortly after birth, meconium ileus is caused by decreased intestinal lumen water volume and decreased secretion of digestive enzymes from the pancreas due to chronic pancreatitis. Found in the respiratory tract, bacterial infections such as Pseudomonas aeruginosa persist because airway clearance decreases due to an increase in the consistency of airway mucus. Chronic inflammation due to the infection promotes airway remodeling and fibrosis, gradually reducing respiratory function and leading to fatal respiratory failure. The life expectancy of CF patients has been prolonged due to the development of symptomatic treatments such as antibiotics, pancreatic digestive enzymes, expectorants, and anti-inflammatory drugs, but the median life expectancy is still about 40 years.
Cystic fibrosis transmembrane conductance regulator (CFTR) is a cyclic AMP (cAMP)-dependent chloride (Cl−) and HCO3− ion channel that dominantly expresses at the apical plasma membrane (PM) of epithelial cells. CFTR is composed of two membrane-spanning domains (MSD1,2), a regulatory domain (R), and two nucleotide-binding domains (NBD1,2). More than 2000 CFTR mutations have been identified and classified as class I to class VII, based on their phenotypes [2]. The most prevalent CFTR mutation, ∆F508–CFTR, destabilizes NBD1 and the NBD–MSD domain–domain interaction, resulting in misfolding of the CFTR protein. ∆F508–CFTR is categorized as Class II, based on the instability at the endoplasmic reticulum (ER). Class II mutations cause abnormal CFTR protein folding at the ER and are recognized as misfolded proteins by the ER quality control (ERQC) system and, consequently, degraded by ER-associated degradation (ERAD). PM-localized rescued ∆F508 (r∆F508)–CFTR by correctors, or low-temperature rescuing, shows Class III (declined channel activity) and Class VI phenotypes. Class VI mutations do not compromise the trafficking to the PM expression and channel activity of the CFTR protein but cause rapid turnover of the CFTR protein at the PM due to accelerated endocytosis and lysosomal degradation by the PM quality control (PMQC) system. Because ubiquitylation levels determine the CFTR degradation both at the ER and PM [3,4], understanding the mechanism of CFTR ubiquitylation serves us the novel therapeutic strategy that could contribute to stabilizing the CFTR and improve the limited efficacy of CF drugs.

2. Biosynthesis of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein

CFTR is translated on the endoplasmic reticulum (ER) membrane and folds into the native conformation (Figure 1). The CFTR folding mechanism consists of the first step in which each domain folds into a metastable state during translation (co-translational domain-wise folding), and the second step in which each domain interacts after translation and folds into the native state as a whole CFTR protein (post-translational coupled-domain folding and assembly) [5,6,7,8]. CFTR undergoes N-glycosylation in the ER and interacts with calnexin (CNX), an ER lectin-like chaperone [9,10]. Cytoplasmic molecular chaperones Hsp70 and Hsp90, and their co-chaperones (Hdj2, p23, FKBP8), interact with the CFTR and assist its folding [11,12,13]. The most common ∆F508 mutation in cystic fibrosis (CF) is a mutation in which the 508th phenylalanine (F508) present in NBD1 is deleted, reducing the structural stability of NBD1 [14]. Since F508 is located on the surface of NBD1 and at the boundary between the NBD1 and intracellular loops of MSD1 and MSD2, it is thought that the ∆F508 mutation also destabilizes the interdomain interaction between NBD1 and MSD1 and MSD2 [7,15]. Translation kinetics also affects CFTR folding efficiency [16]. Ribosomal protein RPL12 knockdown has been reported to reduce the translation rate of CFTR mutants, resulting in partial improvement in ∆F508–CFTR folding [17]. Slowing of nascent polypeptide elongation with low concentrations of cycloheximide or emetine has been observed to improve the folding of ∆F508–CFTR [17].

3. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Endoplasmic Reticulum Quality Control (ERQC)

Misfolded ∆F508–CFTR is retained in the endoplasmic reticulum (ER) by the ERQC system. CFTR export from the ER to the Golgi apparatus requires the CFTR di-acidic ER export motif (563–567aa, YKDAD) recognition by the Sec23/24 complex. CFTR misfolding veils this ER export motif and results in CFTR ER retention [18]. Simultaneously, CFTR misfolding exposes RXR-based ER retention/retrieval motifs and promotes CFTR ER retention [19,20]. ER retention of misfolded CFTR sustains interaction with cytosolic molecular chaperones Hsc70, Hsp70, and CNX [10,21,22,23]. ER retained misfolded CFTR will be ubiquitylated and retro-translocated to the cytoplasm by the Derlin-1 complex and degraded by the proteasome (Figure 2) [3,24,25,26].
Numerous ubiquitin ligases are involved in misfolded CFTR ubiquitylation at the ER (Figure 2). CFTR is ubiquitylated by co-translational and post-translational mechanisms [3,27]. An ER membrane-binding Really Interesting New Gene (RING)-type ubiquitin ligase Ring finger protein 5 (RNF5, also known as RMA1) recognizes the membrane-spanning region of CFTR and is involved in CFTR co-translational ubiquitylation [28]. An RNF5 homolog, Ring finger protein 185 (RNF185), localized at the ER membrane, also interacts with Derlin-1, and is involved in the CFTR co-translational ubiquitylation [29]. An ER membrane-localized RING-type ubiquitin ligase Gp78 (AMFR) has an E4-like activity and extends the CFTR ubiquitin chain produced by RNF5 [30]. A cytosolic chaperone binding ubiquitin ligase C-terminal Hsp-interacting protein (CHIP) recognizes the cytosolic region of CFTR and, especially, is involved in the post-translational ubiquitylation of ∆F508 CFTR–NBD2 [26,28]. The involvement of other ubiquitin ligases (Skp-Cullin-F box (SCFFbx2), synoviolin 1 (SYVN1)) has been reported, but it is not clear if these ubiquitin ligases selectively recognize misfolded ∆F508 CFTR [31,32]. CFTR ubiquitylation at the ER is reversible, and USP19, an ER membrane tail-anchored de-ubiquitylating enzyme (DUB), has been reported to suppress the CFTR ER-associated degradation (ERAD) [33].
CFTR is not only ubiquitylated, but also modified by ubiquitin-like protein SUMO (SUMOylation). Hsp27, a small heat shock protein (sHsp), selectively recognizes ∆F508 CFTR and induces SUMOylation to cooperate with the SUMO E2 enzyme Ubc9. SUMOylated CFTR is ubiquitylated by RNF4, a SUMO-targeted Ub E3 ligase, and undergoes proteasome degradation [34]. Additionally, the Hsp27–Ubc9 complex selectively adds SUMO–2 to Lys447 of unfolded ∆F508–NBD1 [35]. SUMO E3 PIAS (protein inhibitor of activated STAT4) promotes SUMO–1 modification of CFTR and inhibits SUMO–2/3 modification, thereby inhibiting ubiquitylation of CFTR and suppressing its degradation [36].

4. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Plasma Membrane Quality Control (PMQC)

Most of ∆F508–CFTR is eliminated by ER-associated degradation (ERAD), but some ∆F508–CFTR can escape from the endoplasmic reticulum quality control (ERQC) and reach the plasma membrane (PM). PM expression of ∆F508–CFTR has been observed in the airway and intestinal epithelial cells of cystic fibrosis (CF) patients [37]. ∆F508–CFTR folding is temperature-sensitive, and a low-temperature culture (26–30 °C) promotes the functional ∆F508–CFTR PM expression [38]. The CFTR corrector (lumacaftor, etc.), which is the main component of the CF drug Orkambi®, also promotes the PM expression of ∆F508–CFTR [39]. ∆F508–CFTR that appear on the PM can function as an ion channel but is ubiquitylated as an abnormal protein and rapidly removed from the PM [40,41,42]. Class VI CFTR mutants, such as ∆70–CFTR, are normally matured and transported to the PM but undergo ubiquitylation and rapid elimination from the PM [40]. Ubiquitylation promotes CFTR endocytosis and inhibits recycling. Ubiquitylated CFTR is recognized by the endosomal sorting complex required for transport (ESCRT) containing Hepatocyte growth factor-regulated tyrosine kinase substrate (HGS, also known as Hrs) and Tumor susceptibility gene 101 (TSG101) in the endosome and is then sorted to the lysosome for degradation [4,40]. The proteasome also is involved in the degradation of CFTR mutants from the PM, but the mechanism of how these different degradation pathways are selected remains unknown [43,44].
Ubiquitylation of ∆F508–CFTR at the PM involves the chaperone-dependent ubiquitin ligase C-terminal Hsp-interacting protein (CHIP) (Figure 3). ∆F508–CFTR on the PM is partially denatured, and its structural abnormality is recognized by chaperone complexes including Hsc70, Hsp90, and co-chaperones (DNAJA1, HOP, Aha1) [4]. The chaperone complex is vital for the maintenance of cell surface ∆F508–CFTR structural stability and channel function [45]. However, the unfolded cell surface of ∆F508–CFTR continues to bind to the chaperone complex similarly at the ERQC mechanism, and the chaperone-mediated CHIP binding promotes ∆F508–CFTR ubiquitylation [4,46]. It recently has been shown that the ubiquitylation of the unfolded cell surface of CFTR involves the chaperone-independent ubiquitin ligase rififylin (RFFL) (Figure 3) [47]. RFFL has a Fab-1, YGL023, Vps27, and EEA1 (FYVE)-like domain that binds to phosphatidylinositol (PI) 3-phosphate (PI(3)P) and PI(5)P in the N-terminal region, the Really Interesting New Gene (RING) domain which is important for ubiquitin ligase activity in the C-terminal region, and multiple disordered regions within other regions [48]. RFFL does not have a transmembrane domain, but its N-terminal domain is palmitoylated and is localized on the cytoplasmic side of the plasma and endosomal membranes [49,50]. RFFL directly recognizes the NBD1 of CFTR through the N-terminal disordered regions. Interestingly, the recognition by RFFL is dependent on the CFTR conformation, selectively recognizing and ubiquitylating partially denatured NBD1. RFFL knockdown has little effect on the ubiquitylation and degradation of immature ∆F508–CFTR localized at the ER. However, it suppresses the lysosomal degradation of mature ∆F508–CFTR from the PM by dramatically inhibiting the K63-linked polyubiquitylation, which is preferentially involved in lysosomal sorting [47]. Therefore, unlike CHIP, RFFL is thought to function as a PMQC ubiquitin ligase that directly recognizes the structural abnormality of ∆F508–CFTR located at the PM and endosome and directs it to degradation. Added to CHIP and RFFL, the ubiquitin ligases membrane-associated RING-CH 2 (MARCH2), c–CBL, and Nedd4L have been reported to participate in the CFTR degradation at the PM and post-Golgi compartment. However, it remains unclear if these ubiquitin ligases selectively recognize the structural abnormalities of CFTR and play an essential role in the CFTR quality control (Figure 3) [51,52,53,54].
De-ubiquitylating enzyme (DUB) is likely to be involved in the CFTR PMQC mechanism similar to ERQC. Endosome-localized DUB, Ubiquitin Specific Protease 10 (USP10), suppresses ubiquitylation of WT–CFTR in early endosomes and promotes the recycling of CFTR to the PM [55]. Pseudomonas aeruginosa virulence factor Cif, found in patients with CF and chronic obstructive pulmonary disease (COPD), suppresses USP10 activity and promotes CFTR ubiquitylation and lysosomal degradation (Figure 3) [56]. USP10 may recognize the conformational state of CFTR in endosomes and regulate its ubiquitylation level, although the direct evidence remains lacking. DUBs that recognize the structural state of CFTR and selectively deubiquitylates native CFTR have not been identified yet.

5. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators

Thirty years have passed since cystic fibrosis transmembrane conductance regulator (CFTR) was identified as the cystic fibrosis (CF) causative gene in 1989, and the molecular mechanism of CFTR expression and dysfunction due to a genetic mutation is being clarified [57]. During the past seven years, CFTR modulators including Kalydeco® (2012), Orkambi® (2015), Symdeko® (2018) and Trikafta® (2019) have been clinically used to correct the root causes of CF. Kalydeco®, also known as ivacaftor and VX–770, is the first CFTR modulator clinically used and acts as a CFTR potentiator facilitating the channel opening of class III and IV mutants, including G551D–CFTR. Orkambi® is the first CFTR modulator for CF carrying ∆F508–CFTR. It is a combination drug of Kalydeco® and lumacaftor (VX–809), which is a CFTR corrector facilitating the endoplasmic reticulum (ER) export and plasma membrane (PM) expression of the CFTR protein. Symdeko® is also a combination drug of Kalydeco® and tezacaftor (VX–661), which has an improved drug interaction. The CFTR corrector lumacaftor and its analog tezacaftor stabilize the CFTR structure by improving the inter-domain interaction between membrane spanning domain (MSD)1,2 and nucleotide binding domain 1 (NBD1) in addition to the effect of improving the folding of MSD. However, lumacaftor and tezacaftor fail to improve the conformational stability of NBD1 itself [58,59,60]. Actually, both Orkambi® and Symdeco®, which are combined drugs with ivacaftor, have limited effects in clinical use [61]. The recently developed elexacaftor (VX–445) increases the PM expression of ∆F508–CFTR when used in combination with the first-generation CFTR corrector (lumacaftor or tezacaftor) and, thus, may have a different point of action than the first-generation CFTR correctors [62]. Since the effectiveness of the first-generation corrector is synergistically enhanced by the NBD1 stabilization, elexacaftor may have an NBD1 stabilizing effect. Elexacaftor, tezacaftor, and ivacaftor were approved by the Food and Drug Administration (FDA) as Trikafta®. Trikafta® improves the indicator of respiratory function (% forced expiratory volume in one second (FEV1)) by about 14% after administration for four weeks, while Symdeco® improves about 7%, indicating a high clinical efficacy of Trikafta® [62,63].

6. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Cystic Fibrosis (CF) Drugs Target

Since the accelerated cystic fibrosis transmembrane conductance regulator (CFTR) degradation causes the loss of function of CFTR in cystic fibrosis (CF), attenuating the CFTR degradation could be useful for the treatment of CF. However, treatment with proteasome inhibitors suppressing the ∆F508–CFTR endoplasmic reticulum associate degradation (ERAD) fails to restore the CFTR function; instead, they accumulate ubiquitylated ∆F508–CFTR in the cytoplasm and form aggresomes [64]. Conversely, overexpression of the endoplasmic reticulum (ER) molecule chaperone calnexin (CNX) inhibits ∆F508–CFTR ubiquitylation and retro-translocation to the cytoplasm and, consequently, foldable ∆F508–CFTR that can be expressed at the plasma membrane (PM) is accumulated on the ER membrane [10]. Since ubiquitylation is thought to promote the retro-translocation of ∆F508–CFTR, counteracting the CFTR-selective ubiquitylation by regulating ubiquitin ligases could be useful for the treatment of CF [65]. Indeed, in cell line models, knockdown of ubiquitin ligases Ring finger protein 5 (RNF5), C-terminal Hsp-interacting protein (CHIP), or synoviolin 1(SYVN1), involved in ERAD of ∆F508–CFTR enhances the efficacy of the CFTR corrector [32,66]. Seen in mouse models, it has been shown that RNF5 knockout improves ∆F508–CFTR expression and function, resulting in ameliorated intestinal malfunction [67]. Additionally, an RNF5 small molecule inhibitor (Inh–02) improves ∆F508–CFTR expression and function in a primary airway epithelial cell of CF patients [68]. Therefore, CFTR-associated ubiquitin ligase inhibitors are useful as add-on drugs that enhance the limited efficacy of CF drugs, including Orkambi®. CHIP participates in the CFTR ubiquitylation at the ER and PM. However, counteracting CHIP activity may not be preferable for a CF therapeutic approach as its knockout has a deleterious effect [69]. Rififylin (RFFL), another ubiquitin ligase responsible for the CFTR plasma membrane quality control (PMQC), seems to be a promising target for CF treatment because RFFL knockout mice exhibit no abnormal phenotypes [47,70]. Since RFFL knockdown improves ∆F508–CFTR PM stability, RFFL inhibitors also are expected to be CFTR stabilizers, a first-in-class CF drug, which helps maintain functional ∆F508–CFTR at the PM and improves the limited efficacy of the CF drug Orkambi® [71].

7. Conclusions

The majority of cystic fibrosis (CF) in patients is caused by abnormal cystic fibrosis transmembrane conductance regulator (CFTR) folding, thus, understanding of the CFTR protein quality control mechanism requires the identification of new CF therapeutic target molecules which can then contribute to the development of CFTR modulator enhancers based on new molecular mechanisms. Particularly, ubiquitylation of CFTR is complicatedly controlled by many regulatory factors at various locations in the cell, but its selective inhibition can be applied to the treatment of CF. Currently, ubiquitin ligases are focused on potential therapeutic targets for CF, but the number of small molecules that selectively inhibit the ubiquitin ligases is limited. Someday, the use of various modalities, such as nucleic acid medicines, peptide drugs that are effective in inhibiting protein-protein interaction, and degradation inducers such as PROTAC (proteolysis-targeting chimeric molecule), will lead to highly-satisfying CF drug therapy.

Author Contributions

Writing—review and editing, R.F. and T.O.; visualization, R.F.; supervision, T.O. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by JSPS KAKENHI grant numbers 19H03185 and 19H05300 to T.O.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Miquéias, L.-P. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Front. Pharmacol. 2020, 10, 1662. [Google Scholar]
  2. Veit, G.; Avramescu, R.G.; Chiang, A.N.; Houck, S.A.; Cai, Z.; Peters, K.W.; Hong, J.S.; Pollard, H.B.; Guggino, W.B.; Balch, W.E.; et al. From CFTR biology toward combinatorial pharmacotherapy: Expanded classification of cystic fibrosis mutations. Mol. Biol. Cell 2016, 27, 424–433. [Google Scholar] [CrossRef] [Green Version]
  3. Ward, C.L.; Omura, S.; Kopito, R.R. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 1995, 83, 121–127. [Google Scholar] [CrossRef] [Green Version]
  4. Okiyoneda, T.; Barrière, H.; Bagdány, M.; Rabeh, W.M.; Du, K.; Höhfeld, J.; Young, J.C.; Lukacs, G.L. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 2010, 329, 805–810. [Google Scholar] [CrossRef] [Green Version]
  5. Okiyoneda, T.; Lukacs, G.L. Fixing cystic fibrosis by correcting CFTR domain assembly. J. Cell Biol. 2012, 199, 199–204. [Google Scholar] [CrossRef] [Green Version]
  6. Du, K.; Lukacs, G.L. Cooperative assembly and misfolding of CFTR domains in vivo. Mol. Biol. Cell 2009, 20, 1903–1915. [Google Scholar] [CrossRef] [Green Version]
  7. Du, K.; Sharma, M.; Lukacs, G.L. The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat. Struct. Mol. Biol. 2005, 12, 17–25. [Google Scholar] [CrossRef]
  8. He, L.; Aleksandrov, A.A.; Serohijos, A.W.; Hegedus, T.; Aleksandrov, L.A.; Cui, L.; Dokholyan, N.V.; Riordan, J.R. Multiple membrane-cytoplasmic domain contacts in the cystic fibrosis transmembrane conductance regulator (CFTR) mediate regulation of channel gating. J. Biol. Chem. 2008, 283, 26383–26390. [Google Scholar] [CrossRef] [Green Version]
  9. Pind, S.; Riordan, J.R.; Williams, D.B. Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 1994, 269, 12784–12788. [Google Scholar]
  10. Okiyoneda, T.; Harada, K.; Takeya, M.; Yamahira, K.; Wada, I.; Shuto, T.; Suico, M.A.; Hashimoto, Y.; Kai, H. Delta F508 CFTR pool in the endoplasmic reticulum is increased by calnexin overexpression. Mol. Biol. Cell 2004, 15, 563–574. [Google Scholar] [CrossRef]
  11. Loo, M.A.; Jensen, T.J.; Cui, L.; Hou, Y.; Chang, X.B.; Riordan, J.R. Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. EMBO J. 1998, 17, 6879–6887. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Meacham, G.C.; Lu, Z.; King, S.; Sorscher, E.; Tousson, A.; Cyr, D.M. The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. EMBO J. 1999, 18, 1492–1505. [Google Scholar] [CrossRef]
  13. Wang, X.; Venable, J.; LaPointe, P.; Hutt, D.M.; Koulov, A.V.; Coppinger, J.; Gurkan, C.; Kellner, W.; Matteson, J.; Plutner, H.; et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 2006, 127, 803–815. [Google Scholar] [CrossRef] [Green Version]
  14. Qu, B.H.; Thomas, P.J. Alteration of the cystic fibrosis transmembrane conductance regulator folding pathway. J. Biol. Chem. 1996, 271, 7261–7264. [Google Scholar] [CrossRef] [Green Version]
  15. Rabeh, W.M.; Bossard, F.; Xu, H.; Okiyoneda, T.; Bagdany, M.; Mulvihill, C.M.; Du, K.; di Bernardo, S.; Liu, Y.; Konermann, L.; et al. Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function. Cell 2012, 148, 150–163. [Google Scholar] [CrossRef] [Green Version]
  16. Kim, S.J.; Yoon, J.S.; Shishido, H.; Yang, Z.; Rooney, L.A.; Barral, J.M.; Skach, W.R. Protein folding. Translational tuning optimizes nascent protein folding in cells. Science 2015, 348, 444–448. [Google Scholar] [CrossRef] [Green Version]
  17. Veit, G.; Oliver, K.; Apaja, P.M.; Perdomo, D.; Bidaud-Meynard, A.; Lin, S.T.; Guo, J.; Icyuz, M.; Sorscher, E.J.; Hartman, J.L.; et al. Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect. PLoS Biol. 2016, 14, e1002462. [Google Scholar] [CrossRef]
  18. Wang, X.; Matteson, J.; An, Y.; Moyer, B.; Yoo, J.S.; Bannykh, S.; Wilson, I.A.; Riordan, J.R.; Balch, W.E. COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code. J. Cell Biol. 2004, 167, 65–74. [Google Scholar] [CrossRef] [Green Version]
  19. Chang, X.B.; Cui, L.; Hou, Y.X.; Jensen, T.J.; Aleksandrov, A.A.; Mengos, A.; Riordan, J.R. Removal of multiple arginine-framed trafficking signals overcomes misprocessing of delta F508 CFTR present in most patients with cystic fibrosis. Mol. Cell 1999, 4, 137–142. [Google Scholar] [CrossRef]
  20. Kim Chiaw, P.; Huan, L.J.; Gagnon, S.; Ly, D.; Sweezey, N.; Rotin, D.; Deber, C.M.; Bear, C.E. Functional rescue of DeltaF508-CFTR by peptides designed to mimic sorting motifs. Chem. Biol. 2009, 16, 520–530. [Google Scholar] [CrossRef] [Green Version]
  21. Okiyoneda, T.; Niibori, A.; Harada, K.; Kohno, T.; Michalak, M.; Duszyk, M.; Wada, I.; Ikawa, M.; Shuto, T.; Suico, M.A.; et al. Role of calnexin in the ER quality control and productive folding of CFTR; differential effect of calnexin knockout on wild-type and DeltaF508 CFTR. Biochim. Biophys. Acta 2008, 1783, 1585–1594. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Farinha, C.M.; Amaral, M.D. Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. Mol. Cell. Biol. 2005, 25, 5242–5252. [Google Scholar] [CrossRef] [Green Version]
  23. Yang, Y.; Janich, S.; Cohn, J.A.; Wilson, J.M. The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc. Natl. Acad. Sci. USA 1993, 90, 9480–9484. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Jensen, T.J.; Loo, M.A.; Pind, S.; Williams, D.B.; Goldberg, A.L.; Riordan, J.R. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 1995, 83, 129–135. [Google Scholar] [CrossRef] [Green Version]
  25. Wang, B.; Heath-Engel, H.; Zhang, D.; Nguyen, N.; Thomas, D.Y.; Hanrahan, J.W.; Shore, G.C. BAP31 interacts with Sec61 translocons and promotes retrotranslocation of CFTRDeltaF508 via the derlin-1 complex. Cell 2008, 133, 1080–1092. [Google Scholar] [CrossRef] [Green Version]
  26. Meacham, G.C.; Patterson, C.; Zhang, W.; Younger, J.M.; Cyr, D.M. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat. Cell Biol. 2001, 3, 100–105. [Google Scholar] [CrossRef]
  27. Sato, S.; Ward, C.L.; Kopito, R.R. Cotranslational ubiquitination of cystic fibrosis transmembrane conductance regulator in vitro. J. Biol. Chem. 1998, 273, 7189–7192. [Google Scholar] [CrossRef] [Green Version]
  28. Younger, J.M.; Chen, L.; Ren, H.Y.; Rosser, M.F.; Turnbull, E.L.; Fan, C.Y.; Patterson, C.; Cyr, D.M. Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator. Cell 2006, 126, 571–582. [Google Scholar] [CrossRef] [Green Version]
  29. El Khouri, E.; Le Pavec, G.; Toledano, M.B.; Delaunay-Moisan, A. RNF185 is a novel E3 ligase of endoplasmic reticulum-associated degradation (ERAD) that targets cystic fibrosis transmembrane conductance regulator (CFTR). J. Biol. Chem. 2013, 288, 31177–31191. [Google Scholar] [CrossRef] [Green Version]
  30. Morito, D.; Hirao, K.; Oda, Y.; Hosokawa, N.; Tokunaga, F.; Cyr, D.M.; Tanaka, K.; Iwai, K.; Nagata, K. Gp78 cooperates with RMA1 in endoplasmic reticulum-associated degradation of CFTRDeltaF508. Mol. Biol. Cell 2008, 19, 1328–1336. [Google Scholar] [CrossRef] [Green Version]
  31. Yoshida, Y.; Chiba, T.; Tokunaga, F.; Kawasaki, H.; Iwai, K.; Suzuki, T.; Ito, Y.; Matsuoka, K.; Yoshida, M.; Tanaka, K.; et al. E3 ubiquitin ligase that recognizes sugar chains. Nature 2002, 418, 438–442. [Google Scholar] [CrossRef] [PubMed]
  32. Ramachandran, S.; Osterhaus, S.R.; Parekh, K.R.; Jacobi, A.M.; Behlke, M.A.; McCray, P.B. SYVN1, NEDD8, and FBXO2 Proteins Regulate ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitin-mediated Proteasomal Degradation. J. Biol. Chem. 2016, 291, 25489–25504. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Hassink, G.C.; Zhao, B.; Sompallae, R.; Altun, M.; Gastaldello, S.; Zinin, N.V.; Masucci, M.G.; Lindsten, K. The ER-resident ubiquitin-specific protease 19 participates in the UPR and rescues ERAD substrates. EMBO Rep. 2009, 10, 755–761. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Ahner, A.; Gong, X.; Schmidt, B.Z.; Peters, K.W.; Rabeh, W.M.; Thibodeau, P.H.; Lukacs, G.L.; Frizzell, R.A. Small heat shock proteins target mutant cystic fibrosis transmembrane conductance regulator for degradation via a small ubiquitin-like modifier-dependent pathway. Mol. Biol. Cell 2013, 24, 74–84. [Google Scholar] [CrossRef]
  35. Gong, X.; Ahner, A.; Roldan, A.; Lukacs, G.L.; Thibodeau, P.H.; Frizzell, R.A. Non-native Conformers of Cystic Fibrosis Transmembrane Conductance Regulator NBD1 Are Recognized by Hsp27 and Conjugated to SUMO-2 for Degradation. J. Biol. Chem. 2016, 291, 2004–2017. [Google Scholar] [CrossRef] [Green Version]
  36. Gong, X.; Liao, Y.; Ahner, A.; Larsen, M.B.; Wang, X.; Bertrand, C.A.; Frizzell, R.A. Different SUMO paralogues determine the fate of wild-type and mutant CFTRs: Biogenesis versus degradation. Mol. Biol. Cell 2019, 30, 4–16. [Google Scholar] [CrossRef]
  37. Kälin, N.; Claass, A.; Sommer, M.; Puchelle, E.; Tümmler, B. DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis. J. Clin. Investig. 1999, 103, 1379–1389. [Google Scholar] [CrossRef] [Green Version]
  38. Denning, G.M.; Anderson, M.P.; Amara, J.F.; Marshall, J.; Smith, A.E.; Welsh, M.J. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992, 358, 761–764. [Google Scholar] [CrossRef]
  39. Van Goor, F.; Hadida, S.; Grootenhuis, P.D.; Burton, B.; Stack, J.H.; Straley, K.S.; Decker, C.J.; Miller, M.; McCartney, J.; Olson, E.R.; et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. USA 2011, 108, 18843–18848. [Google Scholar] [CrossRef] [Green Version]
  40. Sharma, M.; Pampinella, F.; Nemes, C.; Benharouga, M.; So, J.; Du, K.; Bache, K.G.; Papsin, B.; Zerangue, N.; Stenmark, H.; et al. Misfolding diverts CFTR from recycling to degradation: Quality control at early endosomes. J. Cell Biol. 2004, 164, 923–933. [Google Scholar] [CrossRef] [Green Version]
  41. Glozman, R.; Okiyoneda, T.; Mulvihill, C.M.; Rini, J.M.; Barriere, H.; Lukacs, G.L. N-glycans are direct determinants of CFTR folding and stability in secretory and endocytic membrane traffic. J. Cell Biol. 2009, 184, 847–862. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Sharma, M.; Benharouga, M.; Hu, W.; Lukacs, G.L. Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments. J. Biol. Chem. 2001, 276, 8942–8950. [Google Scholar] [CrossRef] [Green Version]
  43. Benharouga, M.; Haardt, M.; Kartner, N.; Lukacs, G.L. COOH-terminal truncations promote proteasome-dependent degradation of mature cystic fibrosis transmembrane conductance regulator from post-Golgi compartments. J. Cell Biol. 2001, 153, 957–970. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Gentzsch, M.; Chang, X.B.; Cui, L.; Wu, Y.; Ozols, V.V.; Choudhury, A.; Pagano, R.E.; Riordan, J.R. Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator. Mol. Biol. Cell 2004, 15, 2684–2696. [Google Scholar] [CrossRef] [PubMed]
  45. Bagdany, M.; Veit, G.; Fukuda, R.; Avramescu, R.G.; Okiyoneda, T.; Baaklini, I.; Singh, J.; Sovak, G.; Xu, H.; Apaja, P.M.; et al. Chaperones rescue the energetic landscape of mutant CFTR at single molecule and in cell. Nat. Commun. 2017, 8, 398. [Google Scholar] [CrossRef]
  46. Okiyoneda, T.; Apaja, P.M.; Lukacs, G.L. Protein quality control at the plasma membrane. Curr. Opin. Cell Biol. 2011, 23, 483–491. [Google Scholar] [CrossRef] [Green Version]
  47. Okiyoneda, T.; Veit, G.; Sakai, R.; Aki, M.; Fujihara, T.; Higashi, M.; Susuki-Miyata, S.; Miyata, M.; Fukuda, N.; Yoshida, A.; et al. Chaperone-Independent Peripheral Quality Control of CFTR by RFFL E3 Ligase. Dev. Cell 2018, 44, 694–708.e7. [Google Scholar] [CrossRef] [Green Version]
  48. McDonald, E.R.; El-Deiry, W.S. Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proc. Natl. Acad. Sci. USA 2004, 101, 6170–6175. [Google Scholar] [CrossRef] [Green Version]
  49. Araki, K.; Kawamura, M.; Suzuki, T.; Matsuda, N.; Kanbe, D.; Ishii, K.; Ichikawa, T.; Kumanishi, T.; Chiba, T.; Tanaka, K.; et al. A palmitoylated RING finger ubiquitin ligase and its homologue in the brain membranes. J. Neurochem. 2003, 86, 749–762. [Google Scholar] [CrossRef]
  50. Sakai, R.; Fukuda, R.; Unida, S.; Aki, M.; Ono, Y.; Endo, A.; Kusumi, S.; Koga, D.; Fukushima, T.; Komada, M.; et al. The integral function of the endocytic recycling compartment is regulated by RFFL-mediated ubiquitylation of Rab11 effectors. J. Cell Sci. 2019, 132, jcs228007. [Google Scholar] [CrossRef] [Green Version]
  51. Cheng, J.; Guggino, W. Ubiquitination and degradation of CFTR by the E3 ubiquitin ligase MARCH2 through its association with adaptor proteins CAL and STX6. PLoS ONE 2013, 8, e68001. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Ye, S.; Cihil, K.; Stolz, D.B.; Pilewski, J.M.; Stanton, B.A.; Swiatecka-Urban, A. c-Cbl facilitates endocytosis and lysosomal degradation of cystic fibrosis transmembrane conductance regulator in human airway epithelial cells. J. Biol. Chem. 2010, 285, 27008–27018. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Caohuy, H.; Jozwik, C.; Pollard, H.B. Rescue of DeltaF508-CFTR by the SGK1/Nedd4-2 signaling pathway. J. Biol. Chem. 2009, 284, 25241–25253. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Fu, L.; Rab, A.; Tang, L.; Bebok, Z.; Rowe, S.M.; Bartoszewski, R.; Collawn, J.F. ΔF508 CFTR surface stability is regulated by DAB2 and CHIP-mediated ubiquitination in post-endocytic compartments. PLoS ONE 2015, 10, e0123131. [Google Scholar] [CrossRef] [Green Version]
  55. Bomberger, J.M.; Barnaby, R.L.; Stanton, B.A. The deubiquitinating enzyme USP10 regulates the post-endocytic sorting of cystic fibrosis transmembrane conductance regulator in airway epithelial cells. J. Biol. Chem. 2009, 284, 18778–18789. [Google Scholar] [CrossRef] [Green Version]
  56. Bomberger, J.M.; Ye, S.; Maceachran, D.P.; Koeppen, K.; Barnaby, R.L.; O’Toole, G.A.; Stanton, B.A. A Pseudomonas aeruginosa toxin that hijacks the host ubiquitin proteolytic system. PLoS Pathog. 2011, 7, e1001325. [Google Scholar] [CrossRef] [Green Version]
  57. Riordan, J.R.; Rommens, J.M.; Kerem, B.; Alon, N.; Rozmahel, R.; Grzelczak, Z.; Zielenski, J.; Lok, S.; Plavsic, N.; Chou, J.L.; et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 1989, 245, 1066–1073. [Google Scholar] [CrossRef]
  58. Ren, H.Y.; Grove, D.E.; De La Rosa, O.; Houck, S.A.; Sopha, P.; Van Goor, F.; Hoffman, B.J.; Cyr, D.M. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol. Biol. Cell 2013, 24, 3016–3024. [Google Scholar] [CrossRef]
  59. Hudson, R.P.; Dawson, J.E.; Chong, P.A.; Yang, Z.; Millen, L.; Thomas, P.; Brouillette, C.G.; Forman-Kay, J.D. Direct Binding of the Corrector VX-809 to Human CFTR NBD1: Evidence of an Allosteric Coupling between the Binding Site and the NBD1:CL4 Interface. Mol. Pharmacol. 2017, 92, 124–135. [Google Scholar] [CrossRef] [Green Version]
  60. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. Corrector VX-809 stabilizes the first transmembrane domain of CFTR. Biochem. Pharmacol. 2013, 86, 612–619. [Google Scholar] [CrossRef]
  61. Wainwright, C.E.; Elborn, J.S.; Ramsey, B.W.; Marigowda, G.; Huang, X.; Cipolli, M.; Colombo, C.; Davies, J.C.; De Boeck, K.; Flume, P.A.; et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N. Engl. J. Med. 2015, 373, 220–231. [Google Scholar] [CrossRef] [Green Version]
  62. Keating, D.; Marigowda, G.; Burr, L.; Daines, C.; Mall, M.A.; McKone, E.F.; Ramsey, B.W.; Rowe, S.M.; Sass, L.A.; Tullis, E.; et al. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N. Engl. J. Med. 2018, 379, 1612–1620. [Google Scholar] [CrossRef]
  63. Rowe, S.M.; Daines, C.; Ringshausen, F.C.; Kerem, E.; Wilson, J.; Tullis, E.; Nair, N.; Simard, C.; Han, L.; Ingenito, E.P.; et al. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. N. Engl. J. Med. 2017, 377, 2024–2035. [Google Scholar] [CrossRef] [Green Version]
  64. Johnston, J.A.; Ward, C.L.; Kopito, R.R. Aggresomes: A cellular response to misfolded proteins. J. Cell Biol. 1998, 143, 1883–1898. [Google Scholar] [CrossRef] [Green Version]
  65. Nakatsukasa, K.; Huyer, G.; Michaelis, S.; Brodsky, J.L. Dissecting the ER-associated degradation of a misfolded polytopic membrane protein. Cell 2008, 132, 101–112. [Google Scholar] [CrossRef] [Green Version]
  66. Grove, D.E.; Rosser, M.F.; Ren, H.Y.; Naren, A.P.; Cyr, D.M. Mechanisms for rescue of correctable folding defects in CFTRDelta F508. Mol. Biol. Cell 2009, 20, 4059–4069. [Google Scholar] [CrossRef] [Green Version]
  67. Tomati, V.; Sondo, E.; Armirotti, A.; Caci, E.; Pesce, E.; Marini, M.; Gianotti, A.; Jeon, Y.J.; Cilli, M.; Pistorio, A.; et al. Genetic Inhibition of the Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated to F508del Cystic Fibrosis Mutation. Sci. Rep. 2015, 5, 12138. [Google Scholar] [CrossRef]
  68. Sondo, E.; Falchi, F.; Caci, E.; Ferrera, L.; Giacomini, E.; Pesce, E.; Tomati, V.; Mandrup Bertozzi, S.; Goldoni, L.; Armirotti, A.; et al. Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia. Cell Chem. Biol. 2018, 25, 891–905. [Google Scholar] [CrossRef]
  69. Min, J.N.; Whaley, R.A.; Sharpless, N.E.; Lockyer, P.; Portbury, A.L.; Patterson, C. CHIP deficiency decreases longevity, with accelerated aging phenotypes accompanied by altered protein quality control. Mol. Cell. Biol. 2008, 28, 4018–4025. [Google Scholar] [CrossRef] [Green Version]
  70. Ahmed, A.U.; Moulin, M.; Coumailleau, F.; Wong, W.W.; Miasari, M.; Carter, H.; Silke, J.; Cohen-Tannoudji, M.; Vince, J.E.; Vaux, D.L. CARP2 deficiency does not alter induction of NF-kappaB by TNFalpha. Curr. Biol. 2009, 19, R7–R9. [Google Scholar] [CrossRef] [Green Version]
  71. Fukuda, R.; Okiyoneda, T. Peripheral Protein Quality Control as a Novel Drug Target for CFTR Stabilizer. Front. Pharmacol. 2018, 9, 1100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Pharmaceuticals 13 00075 g001 550
Figure 1. Wild type (WT)–cystic fibrosis transmembrane conductance regulator (CFTR) is translated at the ribosome on the endoplasmic reticulum (ER), and the membrane spanning domain (MSD) penetrates the ER membrane. Upon translation, each domain of the CFTR is folded with the assistance of chaperone–cochaperone complexes on the cytoplasmic side and inside of the ER to form a metastable structure (Co-translational folding). After the translation is completed, the domains interact by the action of the chaperones to form a native structure (Post-translational folding). Found in the nucleotide binding domain 1 (NBD1) of WT–CFTR, the ER export motif is exposed and CFTR is transported from the ER to the Golgi apparatus by coat protein complex II (COP II) vesicles.
Figure 1. Wild type (WT)–cystic fibrosis transmembrane conductance regulator (CFTR) is translated at the ribosome on the endoplasmic reticulum (ER), and the membrane spanning domain (MSD) penetrates the ER membrane. Upon translation, each domain of the CFTR is folded with the assistance of chaperone–cochaperone complexes on the cytoplasmic side and inside of the ER to form a metastable structure (Co-translational folding). After the translation is completed, the domains interact by the action of the chaperones to form a native structure (Post-translational folding). Found in the nucleotide binding domain 1 (NBD1) of WT–CFTR, the ER export motif is exposed and CFTR is transported from the ER to the Golgi apparatus by coat protein complex II (COP II) vesicles.
Pharmaceuticals 13 00075 g001
Pharmaceuticals 13 00075 g002 550
Figure 2. The stability of the interaction between nucleotide binding domain 1(NBD1) and membrane spanning domains (MSD1,2) decreases due to the NBD1 structural abnormality in the ∆F508–cystic fibrosis transmembrane conductance regulator (CFTR) mutation. The CFTR-associated E3 ligases recognize the misfolded regions mediated by chaperones and facilitate the co-translational and post-translational ubiquitylation. The endoplasmic reticulum (ER) export motif is folded inside ∆F508–CFTR and, conversely, it stays in the ER due to the exposure of the ER retention motif. Ubiquitylated ∆F508–CFTR is ultimately degraded by proteasome via retrotranslocation to the cytoplasm by the Derlin1– valosin-containing protein(VCP) complex.
Figure 2. The stability of the interaction between nucleotide binding domain 1(NBD1) and membrane spanning domains (MSD1,2) decreases due to the NBD1 structural abnormality in the ∆F508–cystic fibrosis transmembrane conductance regulator (CFTR) mutation. The CFTR-associated E3 ligases recognize the misfolded regions mediated by chaperones and facilitate the co-translational and post-translational ubiquitylation. The endoplasmic reticulum (ER) export motif is folded inside ∆F508–CFTR and, conversely, it stays in the ER due to the exposure of the ER retention motif. Ubiquitylated ∆F508–CFTR is ultimately degraded by proteasome via retrotranslocation to the cytoplasm by the Derlin1– valosin-containing protein(VCP) complex.
Pharmaceuticals 13 00075 g002
Pharmaceuticals 13 00075 g003 550
Figure 3. Wild-type (WT)– cystic fibrosis transmembrane conductance regulator (CFTR) exerts a stable channel function on the plasma membrane (PM). Internalized WT–CFTR could undergo deubiquitylation by ubiquitin Specific Protease 10 (USP10) and, consequently, be recycled to the PM. When P. aeruginosa infection occurs, USP10 is inhibited by CFTR inhibitory factor (Cif) produced by the bacteria, and CFTR turnover is accelerated. The misfolded region of ∆F508–CFTR is recognized by a chaperone complex at the PM. The chaperone complex helps to maintain the channel function of ∆F508–CFTR at the PM but promotes the CFTR elimination from the PM by facilitating the C-terminal Hsp-interacting protein (CHIP)-mediated ubiquitylation. Rififylin (RFFL) is localized at the PM and endosome and promotes endocytosis of ∆F508–CFTR by directly recognizing misfolded-nucleotide binding domain 1 (NBD1) and facilitating K63-linked poly-ubiquitylation. The endocytosed ΔF508–CFTR is invaded into the intraluminal vesicle (ILV) of the multivesicular body (MVB) by endosomal sorting complexes required for transport (ESCRT) proteins such as hepatocyte growth factor-regulated tyrosine kinase substrate (HGS, also known as Hrs) and tumor susceptibility gene 101 (TSG101) and sent to lysosomal degradation.
Figure 3. Wild-type (WT)– cystic fibrosis transmembrane conductance regulator (CFTR) exerts a stable channel function on the plasma membrane (PM). Internalized WT–CFTR could undergo deubiquitylation by ubiquitin Specific Protease 10 (USP10) and, consequently, be recycled to the PM. When P. aeruginosa infection occurs, USP10 is inhibited by CFTR inhibitory factor (Cif) produced by the bacteria, and CFTR turnover is accelerated. The misfolded region of ∆F508–CFTR is recognized by a chaperone complex at the PM. The chaperone complex helps to maintain the channel function of ∆F508–CFTR at the PM but promotes the CFTR elimination from the PM by facilitating the C-terminal Hsp-interacting protein (CHIP)-mediated ubiquitylation. Rififylin (RFFL) is localized at the PM and endosome and promotes endocytosis of ∆F508–CFTR by directly recognizing misfolded-nucleotide binding domain 1 (NBD1) and facilitating K63-linked poly-ubiquitylation. The endocytosed ΔF508–CFTR is invaded into the intraluminal vesicle (ILV) of the multivesicular body (MVB) by endosomal sorting complexes required for transport (ESCRT) proteins such as hepatocyte growth factor-regulated tyrosine kinase substrate (HGS, also known as Hrs) and tumor susceptibility gene 101 (TSG101) and sent to lysosomal degradation.
Pharmaceuticals 13 00075 g003

Share and Cite

MDPI and ACS Style

Fukuda, R.; Okiyoneda, T. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Novel Pharmaceutical Target for Cystic Fibrosis. Pharmaceuticals 2020, 13, 75. https://doi.org/10.3390/ph13040075

AMA Style

Fukuda R, Okiyoneda T. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Novel Pharmaceutical Target for Cystic Fibrosis. Pharmaceuticals. 2020; 13(4):75. https://doi.org/10.3390/ph13040075

Chicago/Turabian Style

Fukuda, Ryosuke, and Tsukasa Okiyoneda. 2020. "Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Novel Pharmaceutical Target for Cystic Fibrosis" Pharmaceuticals 13, no. 4: 75. https://doi.org/10.3390/ph13040075

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop